0.79 USD
▲+0.05+6.25%
盘后 0.77 -1.94%
2026-11-20
市值
$40.80M
市盈率
—
EPS
-0.20
股息率
—
52 周区间
0.69 – 1.57
成交量
357.21K
Beta
0.73
目标价
3.13
52W 低 0.6952W 高 1.57
价格走势

公司简介

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Feds...